Deaths, failed trials and other recent setbacks in the autoimmune space
Novartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while others were set aside for strategic reasons or paused over safety concerns.
comments(0)
5-min edit window · permanent after that